Trial Information

Summary: Phase one study to evaluate the efficacy of Ambrisentan in the treatment and prevention of digital ulcers in patients with systemic sclerosis (scleroderma).

A 28 week study of investigating the efficacy of an oral medication in the treatment and prevention of digital ulcers.

Patient Inclusion Criteria:

  • Aged 18 or older
  • Have the diagnosis of scleroderma (limited or diffuse systemic sclerosis)
  • Have at least one ulcer on the finger(s) at or near the tips that developed in the past 12 wekks
  • Be in good general health

Patient Exclusion Criteria:

  • Certain medications within the past 4 to 6 weeks
  • Certain medical conditions
  • History of Hepatitis B, C, or HIV infection

Contact:

Katharine Arefiev, MD, Cutaneous Autoimmunity Fellow
Stanford University School of Medicine
Department of Dermatology
900 Blake Wilbur Drive, Rm W0024
Stanford, CA 94305
Telephone: 650-724-0964
Email:

Profile Page: Stanford University School of Medicine, Stanford, CA

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 23, 2008 at 3:07:06 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA